Sandoz seeks Health Canada approval for generic semaglutide
What happened
Sandoz applied to Health Canada for approval of generic semaglutide following the patent expiration of Ozempic. Sandoz also released an analysis estimating that over 300 drugs will lose legal protection in Canada over the next decade.
From theglobeandmail.com
Why it matters
Sandoz estimates that prompt availability of cheaper generic drugs could save public and private payers $89-billion across the 300+ drugs, compared to $183-billion without them. The speed of regulatory approval is a concern, as the backlog of generic submissions has doubled in the past year.
Health Canada regulates the approval of generic pharmaceuticals, allowing market entry following patent expiration.
From theglobeandmail.com
Who's involved
- SandozSeeking regulatory approval from Health Canada for generic semaglutide
- Health CanadaDepartment overseeing public health and regulating generic drug approvals
- Novo NordiskManufacturer of Ozempic, whose patent expiration drives the generic market opportunity
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Bristol-Myers SquibbSpeculative
Bristol-Myers Squibb could face increased market supply and price pressure in the GLP-1 sector.
- Eli Lilly and CompanySpeculative
Eli Lilly and Company could face increased market supply and price pressure in the GLP-1 sector.
- Novo NordiskSpeculative
Novo Nordisk might see reduced market exclusivity and revenue due to the generic entry.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Generic semaglutide entry may pressure Eli Lilly's market shareGeneric semaglutide entry may pressure Eli Lilly's market sharePossible
- Generic semaglutide approval may reduce costs for Government of CanadaGeneric semaglutide approval could save public payers $89-billion in drug costsPossible
- Generic semaglutide entry could challenge Novo Nordisk's market shareNovo Nordisk may face reduced revenue from generic semaglutide entry into CanadaPossible
Keep exploring
The entities involved
-
Sandoz
organization
-
Health Canada
Department of the Canadian Government that oversees public health